Eravacycline

Pronunciation: Pronunciation not provided in current evidence.

Generic name: eravacycline
Brand names: XERAVA
Drug class: Intravenous tetracycline-class antibacterial
Form: Intravenous infusion; exact formulation (e.g., powder for concentrate for solution) may vary by country
Route: Intravenous infusion
Legal status: Prescription-only medicine

Availability and supply rules vary by country

Trade names by country: United States

What eravacycline is and how it works

Eravacycline is an intravenous tetracycline-class antibiotic. Its sole approved indication (per current U.S. evidence) is the treatment of complicated intra-abdominal infections (cIAI) in adults caused by susceptible organisms. It is not indicated for complicated urinary tract infections (cUTI). (1)

Eravacycline is administered intravenously in a hospital or clinic setting under the direct oversight of a prescriber. The prescriber must confirm the infection, organism susceptibility, and the patient’s suitability. It is not a first-line agent for all intra-abdominal infections; local guidelines and culture results guide its use.

Mechanism of action: how eravacycline works

Eravacycline is a tetracycline-class antibacterial. Detailed pharmacological data are not included in the current research notes; refer to the label. (1)

What eravacycline is used for

Complicated intra-abdominal infections

Eravacycline is indicated for the treatment of complicated intra-abdominal infections in adults caused by susceptible organisms. It is not approved for use in complicated urinary tract infections. (1)

Before taking eravacycline

Do not take / not appropriate for

Do not receive eravacycline if you have known hypersensitivity to eravacycline, any tetracycline antibiotic, or any excipient in the formulation. (all products) (1)
Do not use eravacycline for the treatment of complicated urinary tract infections; it is not approved for this indication. (all indications) (1)

Tell your clinician about

Any known allergy to tetracyclines or other antibiotics.
Current or planned pregnancy, breastfeeding, or if the patient is a child or adolescent (due to tooth and bone growth risks).
Liver problems or if you are taking anticoagulants (blood thinners) – monitoring may be needed.
All other medicines you are taking, especially strong CYP3A inducers (e.g., rifampin, certain anticonvulsants) because they may reduce eravacycline’s effectiveness.
History of Clostridium difficile-associated diarrhoea or antibiotic-related colitis.
Any other medical conditions, including those not listed, because eravacycline is a tetracycline and carries class‑related risks.

(1)

How to take eravacycline

Eravacycline is always given as an intravenous infusion by a healthcare professional in a clinical setting. You will not self‑administer this medicine.
The dose, duration, infusion schedule, and any hepatic adjustment are determined by the prescriber using the current label and the individual clinical situation.
Do not attempt to adjust the drip rate, request an extra dose, or change the treatment plan yourself. All changes must be made by the treating team.

(1)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)

Missed dose

The supplied research notes do not provide a missed-dose protocol. Tell the clinical team if you think an infusion was missed; they will decide what to do.

Overdose

Overdose in the hospital setting is rare but possible. If an overdose is suspected, the clinical team will provide supportive monitoring and manage any adverse effects. Contact the local poison information service if required. (1)

Side effects

Eravacycline can cause infusion-site reactions and nausea/vomiting. As a tetracycline, it carries class‑related risks including hypersensitivity, tooth and bone effects, and diarrhoea. Contact the clinical team immediately for any serious or unexpected symptoms.

Infusion-site reaction

What to notice: Pain, redness, swelling, or hardness around the intravenous line.

What to do: Tell the healthcare team promptly so the site can be assessed and managed. (1)

Nausea and vomiting

What to notice: Feeling sick or being sick during or after the infusion.

What to do: Report to the team; anti‑sickness medicine may be offered. (1)

Severe or bloody diarrhoea

What to notice: Watery or bloody stools, abdominal cramps, fever – these may appear days after the antibiotic is stopped.

What to do: Urgently inform the medical team. Do not take antidiarrhoeal medicines unless advised. (1)

Allergic reaction

What to notice: Rash, itching, swelling of face/tongue/throat, difficulty breathing, or dizziness.

What to do: Alert the clinical staff immediately; emergency treatment may be needed. (1)

Liver problems

What to notice: Unexplained tiredness, loss of appetite, yellowing of skin/eyes, dark urine, or upper abdominal pain.

What to do: Report these symptoms as soon as they are noticed. (1)

Serious warnings

Life‑threatening hypersensitivity — emergency

Symptoms: Sudden wheezing, chest tightness, throat swelling, severe rash, or collapse shortly after the infusion starts.

Action: Healthcare professionals will observe you during and after the infusion; emergency treatment is immediately available. If symptoms occur after discharge, call emergency services. (1)

Tooth discoloration and bone growth inhibition — warning

Symptoms: Permanent yellow‑grey‑brown tooth staining and reduced bone growth may occur. This is most relevant during tooth development (childhood and adolescence) and pregnancy.

Action: The prescriber will weigh benefits against these risks before using eravacycline in patients under 18 years or during pregnancy. (1)

Clostridioides difficile‑associated diarrhoea — warning

Symptoms: Persistent watery or bloody diarrhoea, abdominal pain, and fever that may develop during or after treatment.

Action: Report symptoms immediately. The clinical team will test for C. difficile and begin appropriate management, which may include stopping eravacycline and starting specific treatment. (1)

Microbial overgrowth and antimicrobial resistance — warning

Symptoms: Secondary infections such as oral thrush or yeast infections may occur. Using eravacycline in the absence of a proven or strongly suspected bacterial infection increases the risk of drug‑resistant bacteria.

Action: The prescriber will limit use to confirmed susceptible infections and monitor for superinfections. (1)

Interactions

Medicine or test	Effect	Action
Strong CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin, St John’s wort)	These medicines can significantly lower blood levels of eravacycline, potentially reducing its antibacterial effect.	Your prescriber will review your current medicines and, if possible, avoid concurrent use. If co‑administration is unavoidable, they may need to monitor for treatment failure. (1)
Anticoagulants (blood thinners such as warfarin)	Tetracyclines may enhance the effect of anticoagulants, increasing the risk of bleeding.	Close monitoring of clotting times is recommended; the dose of the anticoagulant may need adjustment by the prescriber. (1)

Pregnancy, breastfeeding, kidney/liver function, age

Children and adolescents

Eravacycline, like other tetracyclines, can cause permanent tooth discoloration and reversible inhibition of bone growth. It should only be used in patients under 18 years when no safer alternative is available and the specialist judges the benefit to outweigh the risk. (1)

Pregnancy and breastfeeding

Discuss the potential benefits and risks with your prescriber. Eravacycline may affect tooth and bone development in the unborn child or breastfed infant. It should only be used during pregnancy if clearly necessary; breastfeeding may need to be suspended during treatment. (1)

Hepatic impairment

Patients with liver impairment may require dose adjustments; the prescriber will assess liver function before and during treatment and decide on the appropriate regimen. (1)

Monitoring

Before starting

Confirm the diagnosis of complicated intra-abdominal infection and obtain cultures and susceptibility testing where possible.
Assess hepatic function, renal function, pregnancy status, and allergy history.
Review concurrent medications for CYP3A inducers and anticoagulants.
Evaluate the need for tetracycline use in patients under 18 years or those who are pregnant.

During treatment

Monitor for signs of hypersensitivity at each infusion.
Watch for diarrhoea, especially C. difficile‑associated symptoms, and superinfections.
Periodically reassess liver function and clotting times if on anticoagulants.
Re‑evaluate the necessity of continued eravacycline based on culture results and clinical response.

(1)

Storage

Eravacycline vials are stored and handled by hospital pharmacy professionals according to the manufacturer’s instructions and institutional protocols. Patients do not store this medicine at home.

Professional information

Clinician-facing context only. Use the current local label and institutional guidelines for dosing, infusion protocols, and safety monitoring.

All regions

Indication: Complicated intra-abdominal infections

Dose summary: Exact dosing schedules are determined by the prescriber; no universal dose is provided here. Refer to the current U.S. XERAVA label (source US-XERAVA-LABEL-2025) for the approved regimen and administration details. Dosing gaps remain for other regions.

Renal context: Renal dosing adjustments are not detailed in the available research notes; consult the full prescribing information. (1)

Mechanism of action

Hepatic guidance

Dose adjustment for hepatic impairment is discussed in the U.S. label; no generic summary can be provided here.

Overdose note

Overdose in the hospital setting should be managed with supportive care and consultation with a poison center if needed. No specific antidote is noted. (1)

Frequently asked questions

How is eravacycline given?

Eravacycline is an antibiotic that is always given as an intravenous (IV) infusion by a healthcare professional in a hospital or clinic. You will not give yourself this medicine. (1)

What infections does eravacycline treat?

The approved use is complicated intra-abdominal infections (serious infections inside the abdomen) in adults. It is not approved for complicated urinary tract infections. The specific infection and whether eravacycline is right for you will be decided by the treating doctor. (1)

What should I watch for after receiving eravacycline?

Tell your medical team immediately about any new or worsening diarrhoea, especially if it is watery or contains blood, as this could be a sign of a serious gut infection. Also report any allergic reaction symptoms such as rash, swelling, or trouble breathing. Other side effects like nausea or vein irritation are common but should still be mentioned. (1)

Can eravacycline be used in children or during pregnancy?

Tetracyclines like eravacycline can cause permanent staining of teeth and affect bone growth in developing children and unborn babies. It is generally avoided in children under 18 and during pregnancy unless no safer alternative exists. Breastfeeding may need to be paused during treatment. Always discuss the risks with your doctor. (1)

Will eravacycline interact with my other medicines?

Yes. Some medicines (strong CYP3A inducers such as rifampin or certain seizure medications) can lower eravacycline’s effectiveness. It can also enhance the effect of blood thinners like warfarin, increasing bleeding risk. Provide a complete list of all your medicines, including herbal products, to the prescriber. (1)

What is the mechanism of action of eravacycline?

Eravacycline is a tetracycline-class antibacterial. Detailed pharmacological data are not included in the current research notes; refer to the label. (1)

What is the generic name of Eravacycline?

The generic name is eravacycline. It is sold under brand names including XERAVA. (1)

What class of drug is eravacycline?

Eravacycline is classed as: Intravenous tetracycline-class antibacterial. (1)

References

XERAVA (eravacycline) — prescribing informationU.S. Food and Drug Administration · United States · dated 2025-09 · accessed 2026-08-11 · source 1
Eravacycline Injection — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 2
eravacycline — RxNorm normalized drug concept (RXCUI 2055906)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 3

Brand names by country

Single-ingredient eravacycline names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries

United States

Xerava100 mg, 50 mg · tetraphase pharmaceuticals, inc.

View brands in additional countries.